End Cash: The amount of cash held by the company for the given period.
Nurix Therapeutics, Inc. (NRIX) had End Cash of $721.02M for the most recently reported fiscal quarter, ending 2026-08-31.
| Income Statement Financials | |
$673.06M |
|
$549.81M |
|
-- |
|
$673.06M |
|
$113.61M |
|
$559.45M |
|
$3.96M |
|
$563.41M |
|
$563.41M |
|
$549.81M |
|
$549.81M |
|
$549.81M |
|
$549.81M |
|
$559.45M |
|
$563.07M |
|
111.56M |
|
116.15M |
|
$4.93 |
|
$4.73 |
|
| Balance Sheet Financials | |
$1.10B |
|
$19.41M |
|
$91.61M |
|
$1.20B |
|
$130.74M |
|
-- |
|
$96.25M |
|
$226.99M |
|
$968.31M |
|
$968.31M |
|
$968.31M |
|
109.20M |
|
| Cash Flow Statement Financials | |
$447.14M |
|
$0.75M |
|
$25.20M |
|
$247.93M |
|
|
End Cash |
$721.02M |
$473.10M |
|
$31.57M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
8.44 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
83.12% |
|
83.12% |
|
-- |
|
83.71% |
|
81.69% |
|
$442.77M |
|
-- |
|
-- |
|
-- |
|
0.56 |
|
-- |
|
33.65 |
|
2.67 |
|
56.78% |
|
56.78% |
|
46.00% |
|
56.78% |
|
$8.87 |
|
$3.81 |
|
$3.85 |
|